Lantern Pharma LTRN 深 沪
已收盘 10-31 16:00:00 美东时间
4.01
+0.040
+1.01%
华盛通- 最 高4.09
- 今 开3.93
- 成交量 3.23万股
- 最 低 3.85
- 昨 收 3.97
- 总市值 4330.56万
- 52周最高 6.118
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 2.55
- 委 比 47.99%
- 总股本 1079.94万
- 历史最高 24.84
- 量 比 0.16
- 振 幅 6.05%
- 历史最低 2.38
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lantern Pharma Presents Clinical Data From Ongoing Phase 1 Trial Of LP-284 At 25th Annual Lymphoma, Leukemia & Myeloma Congress
AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific antibody therapies, validating LP-284's mechanism of action.A novel differentiated synthetic
10-28 20:51
快讯 | Lantern Pharma股价上涨9.5% 其抗癌药物达到早期试验目标后
Lantern Pharma Shares Rise 9.5% After Co's Cancer Drug Met Early-Stage Trial Go...
09-16 22:16
Lantern Pharma Tumor Treatment Meets Trial Endpoints
Unity Software(U.US) reported fourth-quarter financial results after the market...
09-16 20:47
Lantern Pharma's LP-184 Meets All Phase 1a Endpoints, Shows Clinical Benefit In Hard-to-Treat Cancers And Advances To Phase 2 Trials
LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both monotherapy or synergistic combinations with PARP inhibitors and immunotherapies.Clinical benefit
09-16 20:30
快讯 | Lantern Pharma的LP-184一期1a临床试验在多种晚期实体瘤中达到所有主要终点，具有稳健的安全性特征和令人鼓舞的抗肿瘤活性
Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints ...
09-16 20:29
Lantern Pharma Completes Type C Meeting With FDA, Advancing Pediatric CNS Cancer Trial Including Atypical Teratoid Rhabdoid Tumor
Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that are being advanced using its proprietary computational biology and machine learning platform,
09-03 21:47
Lantern Pharma shares are trading lower. The company reported Q2 financial results.
Lantern Pharma shares are trading lower. The company reported Q2 financial resu...
08-14 23:52
Lantern Pharma Q2 EPS $(0.40) Beats $(0.48) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 17.53 percent. This is a 13.04 percent increase over losses of $(0.46) per share from
08-14 04:36
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers FibroGen (NASDAQ:FGEN) shares rose 20.1% to $10.11 during Monday's aft...
08-12 05:06
Lantern Pharma Completes Early Enrollment in Japan for Lung Cancer Trial Targeting Never-Smokers
Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced the successful completion of targeted
07-31 19:35
